These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
629 related articles for article (PubMed ID: 28704825)
1. Dexamethasone Implants in Diabetic Macular Edema Patients with High Visual Acuity. Sacconi R; Battaglia Parodi M; Casati S; Lattanzio R; Marchini G; Bandello F Ophthalmic Res; 2017; 58(3):125-130. PubMed ID: 28704825 [TBL] [Abstract][Full Text] [Related]
2. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215 [TBL] [Abstract][Full Text] [Related]
3. Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Iacono P; Parodi MB; Scaramuzzi M; Bandello F Br J Ophthalmol; 2017 Jun; 101(6):791-795. PubMed ID: 27625164 [TBL] [Abstract][Full Text] [Related]
4. Dexamethasone implant with fixed or individualized regimen in the treatment of diabetic macular oedema: six-month outcomes of the UDBASA study. Sarao V; Veritti D; Furino C; Giancipoli E; Alessio G; Boscia F; Lanzetta P Acta Ophthalmol; 2017 Jun; 95(4):e255-e260. PubMed ID: 28139100 [TBL] [Abstract][Full Text] [Related]
5. Rapid response to dexamethasone intravitreal implant in diabetic macular edema. Lo Giudice G; Avarello A; Campana G; Galan A Eur J Ophthalmol; 2018 Jan; 28(1):74-79. PubMed ID: 28708221 [TBL] [Abstract][Full Text] [Related]
6. Predictive capacity of baseline hyperreflective dots on the intravitreal dexamethasone implant (Ozurdex®) outcomes in diabetic macular edema: a multicenter study. Fonollosa A; Zarranz-Ventura J; Valverde A; Becerra E; Bernal-Morales C; Pastor-Idoate S; Zapata MA Graefes Arch Clin Exp Ophthalmol; 2019 Nov; 257(11):2381-2390. PubMed ID: 31451909 [TBL] [Abstract][Full Text] [Related]
7. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers. Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792 [TBL] [Abstract][Full Text] [Related]
8. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Zur D; Iglicki M; Busch C; Invernizzi A; Mariussi M; Loewenstein A; Ophthalmology; 2018 Feb; 125(2):267-275. PubMed ID: 28935399 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. Castro-Navarro V; Cervera-Taulet E; Navarro-Palop C; Monferrer-Adsuara C; Hernández-Bel L; Montero-Hernández J BMC Ophthalmol; 2019 Jan; 19(1):15. PubMed ID: 30634940 [TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Gillies MC; Lim LL; Campain A; Quin GJ; Salem W; Li J; Goodwin S; Aroney C; McAllister IL; Fraser-Bell S Ophthalmology; 2014 Dec; 121(12):2473-81. PubMed ID: 25155371 [TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study. Sharma A; Bellala K; Dongre P; Reddy P Int Ophthalmol; 2020 Jan; 40(1):67-72. PubMed ID: 31377905 [TBL] [Abstract][Full Text] [Related]
12. Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study. Dugel PU; Capone A; Singer MA; Dreyer RF; Dodwell DG; Roth DB; Shi R; Walt JG; Scott LC; Hollander DA; BMC Ophthalmol; 2015 Sep; 15():118. PubMed ID: 26337664 [TBL] [Abstract][Full Text] [Related]
13. Early Effects of Dexamethasone Implant on Macular Morphology and Visual Function in Patients with Diabetic Macular Edema. Veritti D; Sarao V; Galiazzo F; Lanzetta P Ophthalmologica; 2017; 238(1-2):100-105. PubMed ID: 28558371 [TBL] [Abstract][Full Text] [Related]
14. Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema. Arıkan Yorgun M; Toklu Y; Mutlu M Int Ophthalmol; 2017 Feb; 37(1):185-196. PubMed ID: 27173834 [TBL] [Abstract][Full Text] [Related]
15. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109 [TBL] [Abstract][Full Text] [Related]
16. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873 [TBL] [Abstract][Full Text] [Related]